CDNA · CareDx, Inc.

The thesis

CareDx, a transplant-diagnostics company, has been repriced on a raised 2026 revenue outlook and a higher preliminary 2027 Medicare rate for its AlloSure kidney test. The case holds if the third-quarter report, estimated for about 3 November 2026, keeps revenue on track for the $490–500 million guide issued on 30 July 2026. A weekly close below $44 would invalidate it.

The shares closed at $62.20 on 8 October 2026 on adjusted daily closes. That is 10.9% below the $69.85 close of 5 October 2026, the 52-week closing high, after an 8.7% fall on 6 October 2026 that GuruFocus reported with no company news behind it. Since BTIG's target raise on 24 September 2026, the only new company items are routine SEC Form 4 filings for tax withholding on vested stock.

The narrative is maturing: the guidance raise, the Medicare rate and the BTIG raise are all known, and the shares have drifted lower from the 5 October 2026 high without fresh news. The stock moves from event to event, on reimbursement decisions and quarterly reports. The early-November report decides whether underlying growth supports a price that has risen 116.3% in three months.

Bullish and bearish views on CareDx, Inc.

The bull case on CareDx, Inc. (CDNA), in brief: Guidance was raised well above the prior range. The bear case: Prior-period revenue boosted the second quarter.

Bull case

• Guidance was raised well above the prior range. On 30 July 2026 CareDx lifted 2026 revenue guidance to $490–500 million from $447–465 million. It lifted adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) guidance to $66–78 million from $43–57 million. Second-quarter revenue was $132 million, up 52% year over year.
• Medicare pricing rose while the wider schedule was cut. Benzinga reported on 23 September 2026 that the preliminary 2027 clinical laboratory fee schedule (CLFS) raises AlloSure to $2,840 from $2,753.25 and leaves AlloMap at $3,240. The Centers for Medicare & Medicaid Services (CMS) put schedule-wide savings at about $1 billion a year.
• The lead bullish analyst kept moving higher. Benzinga's price-target page shows BTIG raising its target three times: $28 to $45 on 16 July 2026, $45 to $60 on 6 August 2026 and $60 to $74 on 24 September 2026. Investing.com reported that the latest raise cited management confidence after the transplant local coverage determination was resolved.
• Test volume grew in the second quarter. CareDx reported about 58,000 tests in the quarter, up 17% year over year (30 July 2026 release).

Bear case

• Prior-period revenue boosted the second quarter. Testing-services revenue of $100 million included $16 million attributable to earlier periods. Excluding it, CareDx put growth at about 28% (30 July 2026 release). The third quarter is the first without that boost and without Lab Products.
• The price sits above the average analyst target. StockAnalysis.com showed an average target of $58.83 across seven analysts as of 5 October 2026, with a range of $46 to $74. The $62.20 close on 8 October 2026 remains above that average.
• The Medicare increase is not final. The 2027 rates published in September 2026 are preliminary, and CMS plans final rates in November 2026.
• Insiders have been net sellers. GuruFocus reported on 6 October 2026 that insiders sold $13.3 million of shares over the prior 12 months with no purchases. SEC Form 4 filings show the chief financial officer had 3,018 shares withheld at $66.23 on 1 October 2026 to cover taxes on vested restricted stock units.

Price setup

The adjusted close on 8 October 2026 was $62.20, 10.9% below the $69.85 52-week closing high of 5 October 2026. The shares are up 116.3% over three months, and the 14-day relative strength index (RSI) stands at 64.3, down from 67.8 on 6 October 2026. The pullback has so far given back only part of the September run that followed the Medicare rate news and the BTIG raise.

The August 2026 closing range of $46.69–$48.61 is the last level where the shares paused before the September advance. A weekly close below $44 would put the price under that range and erase the gains tied to the Medicare rate and the analyst raises.

Crowding is visible in three places. The price sits above the $58.83 average analyst target, the third-quarter report is less than a month away, and insider selling over the past year carried no offsetting purchases. Benzinga flagged large options trades in CareDx among health-care names on 25 September 2026.

Catalysts, next 30 days

• ~22 October 2026, est. The public comment period on CMS's preliminary 2027 CLFS rates closes. Comments could seek to change the AlloSure increase before final rates are set.
• ~3 November 2026, est. CareDx third-quarter 2026 results. The date is not yet announced; the 2025 third-quarter report came on 4 November 2025 after a 21 October 2025 date announcement. This is the first quarter without Lab Products and without the second-quarter prior-period revenue.
• ~30 November 2026, est. CMS publishes final 2027 CLFS rates (November, exact date unconfirmed). The case turns on whether the $2,840 preliminary AlloSure rate survives.

What would change the view

The operating case breaks if CareDx cuts its 2026 revenue guide below $490 million, or if third-quarter testing-services growth falls well short of the roughly 28% underlying second-quarter rate. Final 2027 Medicare rates setting AlloSure below the current $2,753.25 would remove the reimbursement half of the case.

On price, a weekly close below $44 would put the shares under the August 2026 closing range and signal that the repricing has unwound. A new published MolDX restriction on transplant surveillance testing would also break the case, since BTIG's latest raise rested on that coverage being resolved.

What it trades with

CareDx trades mainly on its own reimbursement and earnings events, and the 8.7% fall on 6 October 2026 came with no company or sector news cited. Within diagnostics, the 23 September 2026 CLFS release affected peers differently: Benzinga reported positive updates for both CareDx and BillionToOne. Natera, which sells a competing donor-derived cell-free DNA transplant test, is the closest listed comparison, and a CMS or MolDX decision on transplant testing would likely move both.